ANTX
Income statement / Annual
Last year (2025), AN2 Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, AN2 Therapeutics Inc's net income was -$35.17 M.
See AN2 Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$77.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
-$77.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$24.77 M
|
$40.49 M
|
$54.87 M
|
$29.51 M
|
$16.91 M
|
$6.02 M
|
$29.33 M
|
| General & Administrative Expenses |
$13.34 M
|
$14.07 M
|
$14.76 M
|
$12.75 M
|
$4.67 M
|
$1.27 M
|
$1.73 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.34 M
|
$14.07 M
|
$14.76 M
|
$12.75 M
|
$4.67 M
|
$1.27 M
|
$1.73 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$38.11 M
|
$54.55 M
|
$69.64 M
|
$42.19 M
|
$21.57 M
|
$7.28 M
|
$31.07 M
|
| Cost And Expenses |
$38.11 M
|
$54.55 M
|
$69.64 M
|
$42.26 M
|
$21.57 M
|
$7.28 M
|
$31.07 M
|
| Interest Income |
$2.93 M
|
$5.47 M
|
$0.00
|
$1.35 M
|
$69.00 K
|
$3.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$514.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$54.55 M
|
$69.64 M
|
$77.00 K
|
$0.00
|
$7.28 M
|
$31.07 M
|
| EBITDA |
-$38.11 M |
$3.23 M |
$4.90 M |
-$40.88 M |
-$21.57 M |
-$6.32 M |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.94 M
|
$3.23 M
|
$4.90 M
|
$1.31 M
|
$31.00 K
|
-$6.32 M
|
-$2.74 M
|
| Income Before Tax |
-$35.17 M
|
-$51.32 M
|
-$64.73 M
|
-$40.96 M
|
-$21.54 M
|
-$13.60 M
|
-$33.81 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$35.17 M
|
-$51.32 M
|
-$64.73 M
|
-$40.96 M
|
-$21.54 M
|
-$13.60 M
|
-$33.81 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.16 |
-1.72 |
-2.74 |
-2.79 |
-1.5 |
-0.78 |
-0.3 |
| EPS Diluted |
-1.16 |
-1.72 |
-2.74 |
-2.79 |
-1.5 |
-0.78 |
-0.3 |
| Weighted Average Shares Out |
$30.22 M
|
$29.83 M
|
$23.60 M
|
$15.34 M
|
$18.74 M
|
$18.74 M
|
$18.74 M
|
| Weighted Average Shares Out Diluted |
$30.22 M
|
$29.83 M
|
$23.60 M
|
$15.34 M
|
$18.74 M
|
$18.74 M
|
$18.74 M
|
| Link |
|
|
|
|
|
|
|
